Dr Philippe Wolgen

Since holding office as CEO as of November 2005, Dr Wolgen has repositioned Clinuvel and its corporate strategy. Having been recognised for his strategic mindset and meticulous execution in business, Dr Wolgen brought to the company his international finance experience and access to European capital markets, combined with in-depth analysis and expertise of the pharmaceutical and medical world. He has had vast exposure to equity research in the bio-medical industry.

Over the years he has been involved in various generic pharmaceuticals in Europe, start-up companies and the intellectual property rights, licensing issues associated with orthopaedic and craniofacial medical device companies.

Dr Wolgen holds an MBA awarded by each of Columbia University NY and The London Business School, trained as a surgeon Dr Wolgen holds an MD from the University of Utrecht, the Netherlands.

Dr Wolgen is well equipped to communicate to a wide, cross-border pharmaceutical market. His skill set makes him the ideal candidate to lead the company towards the next critical phase of registration of CUV1647 with FDA, TGA and EMEA.